Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status
| Autor: | Yang Zhao, Jingchuan Zhang, Alan M. Mendelsohn, George Shrady, Lorena Lopez-Gonzalez, Steven R. Feldman, Diane J Martinez, Elizabeth Hoit Marchlewicz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Moderate to severe
Adult Male medicine.medical_specialty Databases Factual Dermatology Etanercept Medication Adherence 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Psoriasis Internal medicine Health care medicine Humans Medical prescription Retrospective Studies 030203 arthritis & rheumatology Plaque psoriasis Adult patients business.industry Adalimumab Health Care Costs Middle Aged medicine.disease Thalidomide Treatment Outcome Female Ustekinumab Apremilast Dermatologic Agents Condition status business medicine.drug |
| Zdroj: | The Journal of dermatological treatment. 32(2) |
| ISSN: | 1471-1753 |
| Popis: | To compare treatment patterns and costs among psoriasis patients with and without metabolic conditions newly initiating a biologic or apremilast.Adult patients included had ≥1 prescription for secukinumab, adalimumab, ustekinumab, etanercept, or apremilast between 01/01/2015 and 08/31/2018 (date of first prescription was index date) and no index drug use in the 12-months pre-index, and continuous enrollment in the 12-month pre-index and 24-month post-index periods. Patients were divided into mutually exclusive treatment cohorts and stratified by their pre-index metabolic condition status. Treatment patterns (adherence, non-persistence, switching, discontinuation, use of combination therapy, and re-initiation) and healthcare costs were compared.Overall, 7773 patients were included; 47.5-56.7% had a metabolic condition. Except for the apremilast group, patients with metabolic conditions had higher discontinuation (secukinumab: 50.6% vs. 43.7%; adalimumab*: 53.9% vs. 48.7%; ustekinumab*: 41.9% vs. 35.1%; etanercept: 42.8% vs. 41.2%; apremilast: 43.1% vs. 46.1%) and switching (secukinumab: 48.1% vs. 41.2%; adalimumab*: 47.8% vs. 41.9%; ustekinumab*: 34.5% vs. 25.3%; etanercept*: 53.6% vs. 51.5%; apremilast: 45.8% vs. 44.6%) than patients without (*Many psoriasis patients initiating biologics or apremilast had metabolic conditions. These patients had higher discontinuation and switching, and significantly higher healthcare costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|